MILAJURINE LINDSAY: Open Payments
NPI 1003958208 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,936 in 69 payments from 31 companies in 2025. Trend: 2023 $850 · 2024 $1,893 · 2025 $2,936
Food & beverage: $2,936
| Company | Payments | Amount |
|---|---|---|
| AOP Health US, LLC | 1 | $695 |
| Medtronic, Inc. | 10 | $426 |
| CeQur Corporation | 1 | $289 |
| Novo Nordisk Inc | 11 | $256 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $145 |
| Insulet Corporation | 1 | $104 |
| BETA BIONICS, INC. | 1 | $103 |
| Tandem Diabetes Care, Inc. | 4 | $100 |
| Lilly USA, LLC | 4 | $85 |
| Corcept Therapeutics | 4 | $73 |
Products named: Rapiblyk, MINIMED 780G, CeQur Simplicity, Kerendia, Ozempic, OMNIPOD, iLet Bionic Pancreas, t:slim X2 Insulin Pump with Control-IQ.
Industry payments across DC — which companies pay providers there.
